Sunday, August 11, 2013

China investigates France's Sanofi for alleged bribery: Xinhua

Related News

  • Top insulin maker Novo caught up in China's widening drug probes

    Thu, Aug 8 2013

  • Lundbeck says China unit visited by authorities in wider probe

    Thu, Aug 8 2013

  • Former senior China official to be prosecuted for graft

    Thu, Aug 8 2013

  • Sanofi says taking China bribery claim 'seriously'

    Thu, Aug 8 2013

  • RPT-WRAPUP 4-China fines milk powder makers $110 mln for price fixing

    Wed, Aug 7 2013

Analysis & Opinion

  • Two-child policy may be too late for China
  • GSK finds toxic side effects in Chinese market
An employee walks into an office of French drugmaker Sanofi in Shanghai August 2, 2013. REUTERS/Aly Song

An employee walks into an office of French drugmaker Sanofi in Shanghai August 2, 2013.

Credit: Reuters/Aly Song

BEIJING | Sat Aug 10, 2013 5:59am EDT

BEIJING (Reuters) - China has started investigating French drugmaker Sanofi SA for allegedly bribing more than 500 Chinese doctors with about 1.7 million yuan ($277,600) of payments to raise sales, China's Xinhua state news agency said on Saturday.

Xinhua cited a health bureau official as saying the team investigating Sanofi would include disciplinary authorities and the Beijing municipal health bureau, and it would look for clinical research programs with lists of patient names and medical reports.

Sanofi said this week it took "very seriously" allegations published in a Chinese newspaper on Thursday that its staff bribed more than 500 doctors in China in 2007 to raise sales.

An anonymous whistleblower told the 21st Century Business Herald newspaper that Sanofi staff paid bribes totaling about 1.7 million yuan to 503 doctors at 79 hospitals in Shanghai, Beijing, Hangzhou and Guangzhou in late 2007.

Sanofi said in a statement it was aware of the report but it said it was premature to comment on events that may have occurred in 2007.

It said it had zero tolerance for any unethical practices.

Chinese investigations into bribery and over-pricing have centered on Britain's GlaxoSmithKline Plc (GSK) but the latest developments suggest they could have a wider impact across the pharmaceuticals industry.

Other companies including Danish drugmaker Novo Nordisk A/S, AstraZeneca Plc, Eli Lilly & Co and Belgium's UCB SA have all reported visits from authorities to their China offices.

Analysts have said the investigation into pharmaceuticals are likely to precede a push by authorities for stricter price controls, which could cut annual growth in drug sales in China by as much as half to 10 percent. ($1 = 6.1230 Chinese yuan)

(Reporting by Koh Gui Qing; Editing by Robert Birsel)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/

Comments (0)

Be the first to comment on reuters.com.

Add yours using the box above.


Source : http://feeds.reuters.com/~r/reuters/healthNews/~3/npAEcclrJUk/story01.htm

Posted by at